Prevalence of thyroid antibodies among healthy middle-aged women: Findings from the Thyroid Study in Healthy Women
Prevalence of thyroid antibodies among healthy middle-aged women: Findings from the Thyroid Study in Healthy Women
复制标题
DOI：
10.1016/1047-2797(94)00110-f
复制
发表时间：
1995-01-01
影响因子：
5.6
通讯作者：
Buhari, Alhaji M.
中科院分区：
文献类型：
--
作者：
Massoudi, Mehran S.;Meilahn, Elaine N.;Buhari, Alhaji M.
自身免疫性甲状腺炎是北美亚临床甲状腺功能减退症最常见的原因，在女性中比男性更常见，并且是冠心病（CHD）发展的危险因素。我们测量了健康女性研究参与者（44 - 54岁）的血清中促甲状腺激素（TSH）和两种甲状腺抗体，甲状腺过氧化物酶和甲状腺球蛋白。我们从1983年至1985年的绝经前基线检查和平均5.7年后（3至7.7年）的随访检查中选择了254例样本。在随访中，95名妇女处于绝经前，98名停止月经至少12个月，61名正在接受绝经后激素治疗。总的来说，在这两个时间点，健康人群中甲状腺抗体的患病率都很高（21%至26%）。有抗体的女性TSH浓度高于无抗体的女性（2.68 +- 1.3 vs 1.51 +- 0.73 mU/L, P < 0.001）；即使在排除亚临床甲状腺功能减退（TSH gt 6.0 mU/L）后，这种关系也具有统计学意义。在随访中，TSH和抗体水平没有因绝经状态或激素治疗使用而不同。鉴于健康中年妇女甲状腺抗体的高患病率，有必要进行长期随访，以确定抗体的存在是否与随后的疾病风险增加有关，特别是冠心病。
Autoimmune thyroiditis is the most common cause of subclinical hypothyroidism in North America, is more common in women than men, and is a risk factor for the development of coronary heart disease (CHD). We measured thyroid-stimulating hormone (TSH) and two thyroid antibodies, thyroid peroxidase and thyroglobulin, in stored sera of the participants (aged 44 to 54 years) of the Healthy Women Study. We selected 254 samples from the premenopausal baseline examination in 1983 to 1985 and from a follow-up examination that occurred an average of 5.7 years later (range, 3 to 7.7 years). At follow-up, 95 women remained premenopausal, 98 had ceased menstruating for at least 12 months, and 61 were taking postmenopausal hormone therapy. Overall, the prevalence of the thyroid antibodies in this healthy population was high at both time points (21 to 26%). Women with antibodies had higher TSH concentrations than did those with no antibodies (2.68 +- 1.3 versus 1.51 +- .73 mU/L, P lt 0.001); this relationship was statistically significant even after excluding those with subclinical hypothyroidism (TSH gt 6.0 mU/L). TSH and antibody levels did not differ by menopausal status or hormone therapy use at follow-up. Given the high prevalence of thyroid antibodies among healthy middle-aged women, long-term follow-up is warranted to ascertain whether the presence of antibodies is associated with subsequent excess risk of disease, in particular, CHD.